40
Participants
Start Date
March 14, 2018
Primary Completion Date
June 27, 2019
Study Completion Date
June 27, 2020
Ticagrelor
After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
Clopidogrel
After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
University of Florida, Jacksonville
Collaborators (1)
AstraZeneca
INDUSTRY
University of Florida
OTHER